Orelabrutinib Production Cost Reports

This report gives the detailed analysis needed to set up an orelabrutinib production plant. It works through the main cost areas, from the cost of orelabrutinib production and the orelabrutinib plant cost to the wider orelabrutinib production plant cost. It also looks at what it takes to run the plant day to day. That covers the production process, raw materials, utilities, infrastructure, machinery & technology, manpower, packaging, transportation, and more.

Orelabrutinib Market Analysis: Demand and Supply Analysis, and Sourcing

Orelabrutinib is a small-molecule, covalent, highly selective inhibitor of Bruton's tyrosine kinase (BTK). It binds cysteine-481 on BTK irreversibly and shuts down B-cell receptor signaling, which is what makes it useful in B-cell malignancies, mainly relapsed or refractory CLL/SLL, MCL, and MZL. InnoCare Pharma markets it as Yinuoke in China and Hibruka in Australia, and it reaches patients as a white oral tablet. First-line CLL/SLL approval in China came recently, and multiple sclerosis trials are running outside China under a Biogen license.

The API comes from a very narrow supplier base. InnoCare holds the manufacturing rights in China and makes the drug at its own Beijing facility, while Biogen handles ex-China MS supply under an in-licensing deal; a few Chinese CDMOs and fine chemical houses provide the specialty intermediates and the piperidine-boronic-acid building block. Reference-standard material is bought by contract research labs from catalog suppliers such as Selleckchem, MedKoo, and Alfa Chemistry. Anyone modeling demand and supply has to weigh patent status, InnoCare's captive route yield, the cost of the tricyclic scaffold, and reimbursement pricing under China's National Reimbursement Drug List (NRDL). On receipt, buyers verify assay by HPLC, related substances, residual solvents, chiral purity, and polymorphic form.

Summary of the Product, Grades, and Uses

The molecular formula for orelabrutinib is C26H25N3O3, and the molar mass is 427.5 g/mol under CAS 1655504-04-3. Physically it is a white to off-white crystalline solid with no distinctive odor, practically insoluble in water but soluble in DMSO, methanol, and other polar aprotic solvents, with a density around 1.21 g/cm³.

Two grades reach the market. Pharmaceutical API grade meets NMPA and TGA specifications and ships to InnoCare for tablet formulation, while reference-standard grade sells in milligram-to-gram quantities to CROs and academic labs. Finished tablets are 50 mg film-coated units under the Yinuoke and Hibruka brands.

Oncology covers three approved indications in China: relapsed/refractory CLL/SLL, R/R MCL, and R/R MZL, all listed on the NRDL. The recent first-line CLL/SLL approval has started to lift patient numbers sharply, and Australia's TGA has approved orelabrutinib for R/R MCL. Combination trials with the BCL2 inhibitor mesutoclax and with R-CHOP for first-line MCL are progressing, and a new drug application for primary immune thrombocytopenia was accepted in China recently. Multiple sclerosis is the second family of indications: Biogen holds worldwide MS and non-China autoimmune rights and is running phase 3 studies of the CNS-penetrant tablet. Reference-standard grade takes small volumes at firmer margins, mostly for labs profiling BTK inhibition.

Main End-Uses of Orelabrutinib

Oncology takes the great majority of orelabrutinib demand, close to 90% of finished tablet volume. R/R CLL/SLL is the largest single indication, and the first-line CLL/SLL approval has begun to raise that share further, while R/R MCL and R/R MZL make up the rest of the approved volume. Patients typically take 150 mg once daily as monotherapy, and combination trials with mesutoclax and R-CHOP are expected to broaden use. Tablet buyers check dissolution, uniformity, assay, and impurity profile against the NMPA and TGA specifications.

Autoimmune and CNS use is the second outlet and remains investigational. Biogen's license covers multiple sclerosis worldwide, and the drug's CNS-penetrant profile is the rationale for the deal. A filing for primary immune thrombocytopenia is in China, and systemic lupus, neuromyelitis optica, and other B-cell conditions are in earlier trials. This work will not consume real tablet volume until phase 3 reads out, but it drives most of the intermediate-scale clinical API demand at InnoCare.

Reference-standard use accounts for the rest of demand. Catalog suppliers such as Selleckchem, MedKoo, and Alfa Chemistry supply gram-scale quantities to academic labs and CROs, which need documented purity above 99%, chiral purity, and characterization by NMR, MS, and elemental analysis. The channel takes very little tonnage but sets the pricing floor for high-specification lots.

Orelabrutinib Market Risks

Supply for orelabrutinib is highly concentrated: InnoCare is effectively the sole commercial producer, and no generic route exists while the composition-of-matter patents run, so any disruption at the Beijing facility reaches every downstream market at once. Pricing pressure inside the China NRDL system trims InnoCare's margin at every renewal cycle. Ex-China oncology entry has been slow, so revenue outside China rests almost entirely on the Biogen MS program reading out. Competition from ibrutinib, acalabrutinib, and zanubrutinib is heavy, Chinese payers can substitute across the class where the clinical evidence allows, and non-covalent BTK inhibitors such as pirtobrutinib add a second competitive front.

Orelabrutinib manufacturing has its own risks as the synthesis pairs a chiral tricyclic scaffold with a piperidine-boronic-acid coupling under Suzuki conditions, and both foul on impure feedstocks. Residual palladium from the Suzuki step has to be scrubbed below ICH Q3D limits, and any breakthrough on the polish column downgrades the batch. The acryloyl warhead on the final compound is moisture- and light-sensitive, so late-stage handling runs under nitrogen and controlled humidity, and the R-configuration at the piperidine center has to be held throughout. Historically, most rejected batches trace back to palladium carryover and related-substance failures rather than to yield.

Orelabrutinib Production Process and Main Cost Drivers

This section traces the full value chain, from intermediate synthesis through Suzuki coupling, chiral resolution or asymmetric synthesis, acryloyl amidation, purification, drying, and GMP packaging.

1. By Suzuki Coupling and Acryloyl Amidation Route: The main inputs are 2,6-dichlorocotacyanide, Boc-protected piperidine-boronic acid, palladium catalyst, 1,4-dioxane solvent, TFA for Boc removal, acryloyl chloride, base & purified water.

Production opens with receipt and QC of the tricyclic scaffold and the Boc-protected piperidine boronic acid. The two are coupled under Suzuki conditions in 1,4-dioxane over a palladium catalyst to give the Boc-protected intermediate. TFA then strips the Boc group, and the free piperidine is amidated with acryloyl chloride and a mild base to install the covalent warhead. Crude API is extracted, washed, and carried into a first crystallization from a mixed solvent.

A palladium-scavenger resin polish drops residual Pd below ICH Q3D limits, and a second crystallization locks the correct polymorph. The dried API is milled to tablet-grade particle size, tested against the NMPA and TGA monograph, and packed under nitrogen. The main levers on cost are boronic-acid quality, palladium catalyst loading, chiral yield, and crystallization recovery.

Main Factors Affecting Orelabrutinib Production Cost

The tricyclic scaffold dominates the raw material line, a custom intermediate with no bulk market whose price reflects the multi-step synthesis behind it. The piperidine-boronic-acid building block is the next major cost, shipped from a narrow set of specialty suppliers. Palladium catalyst is a real unit cost, and it has to be reclaimed through metal-refining partners for the plant economics to work. Acryloyl chloride is cheap per kilogram but hazardous to handle, and solvent recovery on 1,4-dioxane matters because the solvent-to-product ratio at coupling is high. GMP documentation, testing, and regulatory filings are carried as fixed overhead that is heavy relative to API tonnage, and on the testing side, chiral HPLC, ICP-MS for palladium, and related-substance HPLC make up most of the spend.

Unit cost also moves with the palladium and acryloyl chloride markets, and any tightening in specialty boronic-acid supply pushes up the tricyclic-step cost. Shifting toward MS clinical-supply lots adds testing, chain-of-custody documentation, and smaller-batch overhead. At the small batch sizes typical of an oncology API, reactor on-stream time weighs heavily, and the GMP infrastructure only becomes economic at moderate scale. Qualifying supply for Biogen's MS program took months of on-site audit work. Because the cleanroom, glovebox, and Pd-polish equipment carry heavy fixed overhead, utilization ultimately decides the unit cost.

Raw Materials for Orelabrutinib Production Plant and its Procurement

The tricyclic scaffold is the primary feedstock, a custom intermediate produced by Chinese specialty fine chemical suppliers under long-term contracts with InnoCare, and its price reflects the underlying multi-step chemistry and the low volume base. The piperidine-boronic acid comes from a narrow set of specialty suppliers in China, India, and Europe, and its specifications cover assay, water content, palladium residue, and related isomers, since any residual isomer carries through to the API. Palladium catalyst ships from precious-metal producers such as Johnson Matthey and BASF, usually as a supported catalyst on carbon, and TFA, acryloyl chloride, 1,4-dioxane, and base come from bulk fine chemical suppliers.

The cheapest scaffold is not always the cheapest route to finished API. A scaffold with elevated related substances raises carryover through the Suzuki coupling, adds purification duty, and increases off-grade output. Boronic-acid quality matters too, since a lot with elevated isomer content lowers coupling yield, and palladium recovery efficiency feeds straight into unit cost because of the metal's value. Taken together, scaffold assay, boronic-acid isomer purity, Pd resin loading, and crystallization solvent quality account for most of the variable cost.

Contracts specify scaffold purity, boronic-acid isomer limits, water content, and residual metals, and every incoming lot is quarantined until QC release. Vendor qualification for a GMP API plant includes on-site audits, impurity-profile review, and lot-to-lot monitoring, and long-term agreements with the scaffold suppliers help steady both cost and timing. Siting the plant near a fine chemical and CDMO cluster in Beijing, Shanghai, or Zhejiang adds real freight, communication, and compliance advantages over a stand-alone site.

Sustainability and Regulatory Requirements

Environmental and occupational concerns center on 1,4-dioxane use, acryloyl chloride handling, and spent palladium catalyst. Standard controls rely on closed handling systems, activated-carbon vent scrubbers, dioxane recovery loops, and metals reclamation on spent Pd resin. Wastewater carries residual amide solvents, halogenated species, and trace metals that need chemical and biological treatment. Heat integration on the crystallization trains cuts steam use, and recovering dioxane above 90% addresses the biggest single environmental cost.

Regulatory obligations follow from the API's use in approved oncology products. In China, the API sits under NMPA cGMP oversight and the manufacturer holds a Drug Master File, while in Australia the TGA has approved the finished product under GMP conditions and applies ICH Q3A, Q3C, and Q3D limits. The Biogen MS collaboration will require US FDA IND and eventual NDA filings, plus an EU MAA under EMA, with ex-China supply qualified against 21 CFR 211 and EU GMP Annex 1. Where required, sites carry ISO 14001 and ISO 45001 certification. No USP or EP monograph exists yet because the molecule is still under patent.

CAPEX and OPEX for an Orelabrutinib Production Plant

The plant needs a multi-step synthesis train with a palladium polish and a controlled finishing line. It starts with scaffold and boronic-acid storage, a glass-lined Suzuki coupling reactor with inert-gas blanketing, a Boc deprotection vessel, and an acryloyl amidation reactor under nitrogen. From there come filtration and centrifuge units, two crystallization trains, a palladium-scavenger polish column, chiral chromatography where required, a nitrogen-purged mill, and a controlled-humidity packing line. Utilities cover clean steam, purified water, WFI-grade water, chilled brine, nitrogen, HEPA-filtered cleanroom air, and a thermal oxidizer for solvent vents. A laboratory block typically houses chiral HPLC, ICP-MS, GC for residual solvents, moisture titrators, and related-substance HPLC, while civil works provide cGMP cleanroom process bays, gowning areas, a controlled-access API warehouse, bunded solvent farms, and QC labs.

Operating cost is set by the same materials and control points that shape the process. The variable side is dominated by the scaffold, boronic acid, catalyst, TFA, acryloyl chloride, dioxane, and base, alongside WFI water, labor, GMP documentation, testing, maintenance, wastewater treatment, packaging, and freight. Cost per saleable kilogram then turns on batch cycle time, coupling yield, and palladium recovery. Plant-to-plant differences come down to capacity, the choice between chiral synthesis and resolution, Pd polish design, cleanroom class, and regulatory scope. Scaffold price, coupling yield, Pd recovery, dioxane recovery, GMP overhead, and testing then determine the running cost.

Plant Location and Investment Factors

A workable site sits near a reliable tricyclic-scaffold supplier and within a fine chemical and CDMO cluster. A trained cGMP workforce is essential. Beijing, Shanghai, Zhejiang, and Jiangsu cover this today for InnoCare, and India's Hyderabad and Ahmedabad clusters would suit a future generic-route entrant. The site also needs GMP-grade wastewater treatment for halogenated and metal-bearing streams, and good road, air, and port access for temperature-controlled shipment to formulation sites and Biogen's fill-finish partners.

The core investment choice is whether to run API only or to integrate scaffold synthesis upstream. An API-only plant is cheaper to build but leaves margin exposed to scaffold price swings, whereas backward integration raises CAPEX but locks in supply. The choice between chiral synthesis and resolution at the piperidine center also changes CAPEX and yield. Scale has to match the oncology market plus a buffer for the MS phase-3 read-outs, and qualifying supply for Biogen MS can take a year or more. Ultimately, the economics rest on captive supply to InnoCare and license-linked supply to Biogen.

Major Orelabrutinib Producing Regions

China is the sole commercial production region for orelabrutinib. InnoCare runs API and formulation manufacturing in Beijing, with clinical-supply lots handled through partner CDMOs, and the molecule is not made outside China at commercial scale. If the MS phase-3 program reads out, Biogen will need to qualify one or more ex-China API suppliers. Reference-standard material is finished by catalog suppliers in the US, Europe, India, and China from small quantities sourced through licensed channels or independent CRO synthesis; bulk API is made at InnoCare's Beijing facility, while research-grade lots run on smaller lines at the catalog houses. Australia is the first ex-China tablet market under the TGA approval.

Key Orelabrutinib Producers

InnoCare Pharma Limited

• Discovered orelabrutinib and holds worldwide oncology rights and China autoimmune rights, producing it commercially at its Beijing API and formulation facility.
• Supplies the Yinuoke tablet across China for R/R CLL/SLL, R/R MCL, R/R MZL & first-line CLL/SLL, and the Hibruka tablet in Australia under the TGA approval.
• Its cost position rests on captive scaffold sourcing, in-house chiral synthesis & the ability to run GMP campaigns at clinical and commercial scale on one site.
• Regulatory record covers NMPA cGMP certification, TGA approval, Drug Master File filings & NRDL listing for all three approved oncology indications.

Biogen Inc.

• Holds the worldwide license for orelabrutinib in multiple sclerosis and certain autoimmune indications outside China, under a collaboration with InnoCare.
• Draws supply from InnoCare's Beijing manufacturing for phase 3 MS trials, with plans to qualify ex-China API suppliers as the program moves toward filing.
• Its cost on MS supply is set by the license economics with InnoCare rather than by manufacturing, since Biogen is not a small-molecule API producer.
• Regulatory work covers US IND filings, EU CTA submissions & the planned NDA/MAA package if the MS phase 3 reads out.

Selleckchem

• Distributes reference-standard orelabrutinib in milligram-to-gram quantities for BTK research, drug-discovery selectivity screens & academic labs.
• Ships from Houston, with warehousing in China, Europe & Japan for rapid delivery to research customers.
• Competes on catalog breadth, next-day shipment & full analytical characterization with NMR, MS & HPLC data packs.
• Quality work covers assay above 99%, chiral purity confirmation & lot-specific certificates of analysis.

MedKoo Biosciences

• Supplies reference-standard orelabrutinib for preclinical research from its US base, catalog code 36978.
• Sources from qualified fine chemical partners, with in-house QC on incoming lots and lot-to-lot release under ISO 9001 process controls.
• Competes on cGMP-adjacent documentation, custom synthesis for larger research quantities & fast quotation on custom lot sizes.
• Quality controls cover HPLC assay, related substances, residual solvents & customer-specific certificate of analysis.

Alfa Chemistry

• Ships CAS 1655504-04-3 orelabrutinib in research quantities to academic laboratories, CROs & industrial R&D groups.
• Distributes from Ronkonkoma, New York, with partners in China & Europe for regional coverage.
• Competes on catalog reach, small-quantity availability from 5 mg upward & bundled analytical documentation.
• Quality work covers assay confirmation, related-substances profile & basic characterization data.

BOC Sciences

• Provides orelabrutinib and custom-synthesis services from its New York operations and China production base.
• Serves academic & industrial R&D customers, with scale-up to gram and kilo lots on request.
• Competes on process-chemistry expertise, custom-lot flexibility & bundled analytical services for BTK-family compounds.
• Quality documentation covers HPLC assay, chiral purity where requested, residual solvents & elemental impurities.